New Data Shows STELARAÂ ustekinumab Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease

HORSHAM Pa. Feb. 17 2017 PRNewswire Janssen Biotech Inc. announced today new twoyear data from the ongoing IMUNITI longterm extension LTE study evaluating the efficacy and safety of subcutaneous SC STELARAÂ ustekinumab in adult patients with moderately to...